Search results for "HEREDITARY"

showing 10 items of 650 documents

Two graphs with a common edge

2014

Let G = G1 ∪ G2 be the sum of two simple graphs G1,G2 having a common edge or G = G1 ∪ e1 ∪ e2 ∪ G2 be the sum of two simple disjoint graphs G1,G2 connected by two edges e1 and e2 which form a cycle C4 inside G. We give a method of computing the determinant det A(G) of the adjacency matrix of G by reducing the calculation of the determinant to certain subgraphs of G1 and G2. To show the scope and effectiveness of our method we give some examples

Discrete mathematicsBlock graphadjacency matrixcycleApplied MathematicsSymmetric graphpathComparability graphgraphdeterminant of graphlaw.inventionCombinatoricsPathwidthlawOuterplanar graphLine graphQA1-939Discrete Mathematics and CombinatoricsMathematicsMathematicsUniversal graphDistance-hereditary graphDiscussiones Mathematicae Graph Theory
researchProduct

A Graph Based Algorithm For Intersection Of Subdivision Surfaces

2003

Computing surface intersections is a fundamental problem in geometric modeling. Any boolean operation can be seen as an intersection calculation followed by a selection of the parts necessary for building the surface of the resulting object. A robust and efficient algorithm to compute intersection on subdivision surfaces (surfaces generated by the Loop scheme) is proposed here. This algorithm relies on the concept of a bipartite graph which allows the reduction of the number of faces intersection tests. Intersection computations are accelerated by the use of the bipartite graph and the neighborhood of intersecting faces at a given level of subdivision to deduce intersecting faces at the fol…

Discrete mathematicsFoster graph[INFO.INFO-DS]Computer Science [cs]/Data Structures and Algorithms [cs.DS][INFO.INFO-DS] Computer Science [cs]/Data Structures and Algorithms [cs.DS][ INFO.INFO-DM ] Computer Science [cs]/Discrete Mathematics [cs.DM][INFO.INFO-DM]Computer Science [cs]/Discrete Mathematics [cs.DM]Intersection number (graph theory)Intersection graphlaw.inventionCombinatorics[INFO.INFO-DM] Computer Science [cs]/Discrete Mathematics [cs.DM]IntersectionlawHomeomorphism (graph theory)Subdivision surfaceCircle graphAlgorithmComputingMilieux_MISCELLANEOUS[ INFO.INFO-DS ] Computer Science [cs]/Data Structures and Algorithms [cs.DS]ComputingMethodologies_COMPUTERGRAPHICSMathematicsDistance-hereditary graph
researchProduct

Core-Shell Arginine-Containing Chitosan Microparticles for Enhanced Transcorneal Permeation of Drugs

2019

Chitosan oligosaccharide (C) was functionalized with L-arginine (A) and short hydrocarbon chains (C-8) to design an amphiphilic copolymer, henceforth CAC(8), leading to microparticles (MPs) consisting of an arginine-decorated hydrophilic shell and inner hydrophobic domains allowing the encapsulation of high amount hydrophobic drugs such as sorafenib tosylate (>10% w/w). L-arginine side chains were selected in order to impart the final MPs enhanced transcorneal penetration properties, thus overcoming the typical biological barriers which hamper the absorption of drugs upon topical ocular administration. The mucoadhesive properties and drug release profile of the CAC(8) MPs (CAC(8)-MPs) were …

Drug3003congenital hereditary and neonatal diseases and abnormalitiesArginineSwinemedia_common.quotation_subjectamphiphilic copolymerPharmaceutical ScienceL-arginineAdministration Ophthalmic02 engineering and technologyArginine030226 pharmacology & pharmacyCorneaChitosan03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineMucoadhesionSide chainAnimalsskin and connective tissue diseasesProtein Kinase Inhibitorsmedia_commonMucin-3microparticlesDrug CarriersMucinnutritional and metabolic diseasesSorafenibPermeation021001 nanoscience & nanotechnologyCombinatorial chemistryBioavailabilityDrug LiberationmicroparticlechemistrySettore CHIM/09 - Farmaceutico Tecnologico Applicativoocular administrationchitosan0210 nano-technologymucoadhesion
researchProduct

Dérivé de la bléomycine générant moins de ROS ? Moins de fibrose ? Une alternative dans le développement d’une thérapie anticancéreuse efficace mais …

2010

Deglycobleomycin (DBLM), the aglycon of the glycopeptide antitumor drug bleomycin (BLM), was first used since 1980 during comparative studies between BLM and DBLM in order to elucidate the role of the sugar component in the mechanism of action of BLM. In fact, the deglycosylation of BLM reduce the toxicity of this molecule and fails to produce reactive oxygen species, responsible for pulmonary fibrosis, and for anti-neoplastic activity of BLM. This causes toxic DNA lesions and ultimately leads to cell death. The therapeutic use of BLM is limited by a dose-dependent lung toxicity that eventually leads to fibrosis. Testing BLM-derivative molecules and defining their molecular mechanisms invol…

Drugcongenital hereditary and neonatal diseases and abnormalitiesCancer Researchurogenital systemmedia_common.quotation_subjectnutritional and metabolic diseasesHematologyGeneral MedicineBleomycinmedicine.diseaseMolecular biologychemistry.chemical_compoundOncologychemistryMechanism of actionApoptosisFibrosisPulmonary fibrosisToxicitymedicineRadiology Nuclear Medicine and imagingmedicine.symptomCytotoxicitymedia_commonBulletin du Cancer
researchProduct

Empirical mode decomposition and neural network for the classification of electroretinographic data

2013

The processing of biosignals is increasingly being utilized in ambulatory situations in order to extract significant signals' features that can help in clinical diagnosis. However, this task is hampered by the fact that biomedical signals exhibit a complex behaviour characterized by strong non-linear and non-stationary properties that cannot always be perceived by simple visual examination. New processing methods need be considered. In this context, we propose to apply a signal processing method, based on empirical mode decomposition and artificial neural networks, to analyse electroretinograms, i.e. the retinal response to a light flash, with the aim to detect and classify retinal diseases…

EngineeringAchromatopsiaBiomedical EngineeringContext (language use)Settore FIS/03 - Fisica Della MateriaHilbert–Huang transformRetinal DiseasesNight BlindnessElectroretinographyMyopiamedicineHumansComputer visionCongenital stationary night blindnessSignal processingArtificial neural networkbusiness.industryVisual examinationEye Diseases HereditaryGenetic Diseases X-LinkedSignal Processing Computer-AssistedPattern recognitionmedicine.diseaseSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Computer Science Applicationselectroretinogram empirical mode decomposition artificial neural network Achromatopsia Congenital Stationary Night BlindnessClinical diagnosisNeural Networks ComputerArtificial intelligencebusinessMedical & Biological Engineering & Computing
researchProduct

Losing DNA methylation at repetitive elements and breaking bad

2021

Abstract Background DNA methylation is an epigenetic chromatin mark that allows heterochromatin formation and gene silencing. It has a fundamental role in preserving genome stability (including chromosome stability) by controlling both gene expression and chromatin structure. Therefore, the onset of an incorrect pattern of DNA methylation is potentially dangerous for the cells. This is particularly important with respect to repetitive elements, which constitute the third of the human genome. Main body Repetitive sequences are involved in several cell processes, however, due to their intrinsic nature, they can be a source of genome instability. Thus, most repetitive elements are usually meth…

EpigenomicsGenome instabilityHeterochromatinSatellitesReviewRepetitive DNABiologyQH426-47003 medical and health sciencesLINE-10302 clinical medicineDNA hypomethylationGeneticsHumansEpigeneticsAutism spectrum disorderRepeated sequenceMolecular BiologyRepetitive Sequences Nucleic Acid030304 developmental biologyCancerGenetics0303 health sciencesHereditary diseasesDNA MethylationChromatinChromatinSettore BIO/18 - GeneticaLong Interspersed Nucleotide ElementsICF syndromeDNA methylationHuman genomeAlzheimer’s disease030217 neurology & neurosurgeryNeuropsychiatric disordersDNA hypomethylationEpigenetics & Chromatin
researchProduct

Extensive molecular analysis of patients bearing CFTR-related disorders.

2012

Cystic fibrosis transmembrane conductance regulator (CFTR)–related disorders (CFTR-RDs) may present with pancreatic sufficiency, normal sweat test results, and better outcome. The detection rate of mutations is lower in CFTR-RD than in classic CF: mutations may be located in genes encoding proteins that interact with CFTR or support channel activity. We tested the whole CFTR coding regions in 99 CFTR-RD patients, looking for gene mutations in solute carrier (SLC) 26A and in epithelial Na channel (ENaC) in 33 patients who had unidentified mutations. CFTR analysis revealed 28 mutations, some of which are rare. Of these mutations, RT-PCR demonstrated that the novel 1525-1delG impairs exon 10 s…

Epithelial sodium channelcongenital hereditary and neonatal diseases and abnormalitiesCystic fibrosis CFTR SLC26A SCNNCystic FibrosisAnion Transport ProteinsDNA Mutational Analysismolecular analysiCystic Fibrosis Transmembrane Conductance RegulatorGene mutationPathology and Forensic Medicinecongenital bilateral absence of vasa deferentesExonGene Frequencydisseminated bronchiectasiscongenital bilateral absence of vasa deferenteHumansTrypsinmolecular analysisEpithelial Sodium ChannelsGeneCells CulturedGenetic Association StudiesGeneticsbiologydisseminated bronchiectasiEpithelial Cellsrespiratory systemrecurrent pancreatitidigestive system diseasesCystic fibrosis transmembrane conductance regulatorrespiratory tract diseasesSolute carrier familyCFTR related disordersTrypsin Inhibitor Kazal PancreaticCase-Control StudiesRNA splicingMutationbiology.proteinMolecular MedicineCFTR related disorderSLC26 familyCarrier ProteinsNa channel ENaCMinigenerecurrent pancreatitis
researchProduct

The Epithelial Mesenchymal Transition Process in Wilms Tumor

2011

Background Until now, only a few mouse-transplanted human tumors or experimental Wilms tumor (WT) cell lines have been described. The aim of this study was to show the biological behavior, including histology, immunohistochemistry (IHC), and molecular biology, of a WT including the original tumor and metastasis transferred into nude mice and followed for successive generations in xenografts. Methods A WT metastasis was xenotransplanted into nude mice and the mice was monitored for 7 passages over a period of 29 months; the original neoplasm was comparatively studied. The morphology was evaluated by optical and electron microscopy. The protein expression was analyzed by immunohistochemistry …

Epithelial-Mesenchymal TransitionHistologyDNA Mutational AnalysisMice NudeCell Growth ProcessesWilms TumorBone and BonesPathology and Forensic MedicineMetastasisMicemedicineAnimalsHumansEpithelial–mesenchymal transitionNeoplasm MetastasisOncogene ProteinsN-Myc Proto-Oncogene ProteinTissue microarrayChemistryMesenchymal stem cellNuclear ProteinsEye Diseases HereditaryWilms' tumorHistologyStriated muscle cell differentiationMicroarray Analysismedicine.diseaseImmunohistochemistryXenograft Model Antitumor AssaysKidney NeoplasmsWnt ProteinsRadiusMedical Laboratory TechnologyMutationCancer researchImmunohistochemistrySignal TransductionApplied Immunohistochemistry & Molecular Morphology
researchProduct

An evidence based therapeutic approach to hereditary and acquired angioedema

2014

Purpose of review Hereditary angioedema (HAE) due to C1 esterase inhibitor (C1-INH) deficiency (HAE-C1-INH), HAE with normal C1-INH, and acquired angioedema due to C1-INH deficiency are rare but important diseases that can be associated with significant morbidity and mortality. Research into the pathogenesis of angioedema has expanded greatly and has led to new clinical trials with novel therapeutic agents and strategies. Recent findings Strategies for managing HAE-C1-INH are aimed at treating acute attacks or preventing attacks through the use of prophylactic treatment. Agents available in Europe for treating acute attacks include plasma-derived C1-INH concentrates, a bradykinin B2 recepto…

Evidence-based practiceImmunologyBradykininBioinformaticsPathogenesischemistry.chemical_compoundTherapeutic approachBradykinin B2 Receptor AntagonistsHumansImmunology and AllergyMedicineheterocyclic compoundsRandomized Controlled Trials as TopicEvidence-Based MedicineAngioedemabusiness.industryAngioedemas HereditaryAntagonistbiochemical phenomena metabolism and nutritionrespiratory systembacterial infections and mycosesmedicine.diseaserespiratory tract diseasesClinical trialchemistryHereditary angioedemaKallikreinsmedicine.symptombusinessComplement C1 Inhibitor ProteinCurrent Opinion in Allergy & Clinical Immunology
researchProduct

Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi® ) in the treatment of von Wille…

2002

Summary. The goal of therapy in patients with von Willebrand disease (vWD) is to correct the dual defect of primary haemostasis and intrinsic coagulation reflected by low levels of von Willebrand factor (vWF) and factor VIII coagulant activity (FVIII:C). Factor VIII/von Willebrand factor (FVIII/vWF) concentrates are currently the treatment of choice in vWD patients unresponsive to desmopressin (DDAVP). However, only few studies on their clinical use are available so far. The main objective of this study was to retrospectively evaluate the clinical efficacy of a highly purified, doubly virus-inactivated FVIII/vWF concentrate with a high content of FVIII/vWF (Fanhdi®). Twenty-two patients wit…

Excessive Bleedingcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtybiologybusiness.industryRetrospective cohort studyHematologyGeneral Medicinemedicine.diseaseGastroenterologyVirusSurgeryVon Willebrand factorCoagulationhemic and lymphatic diseasesInternal medicinebiology.proteinVon Willebrand diseaseMedicinebusinessAdverse effectDesmopressinGenetics (clinical)medicine.drugHaemophilia
researchProduct